Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18618906 | 1.00 | PNP (0.40) | PNPCDK2FEN1JAK2JAK1 | |
| SCHEMBL18617524 | 1.00 | PNP (0.40) | PNPCDK2FEN1JAK2JAK1 | |
| SCHEMBL18617484 | 1.00 | PNP (0.40) | PNPCDK2FEN1JAK2JAK1 | |
| SCHEMBL19295486 | 0.77 | CDK2 (0.54) | CDK2MCHR1 | |
| SCHEMBL18620064 | 0.77 | CDK2 (0.54) | CDK2MCHR1 | |
| SCHEMBL19295485 | 0.77 | CDK2 (0.54) | CDK2MCHR1 | |
| SCHEMBL18586225 | 0.76 | MPO (0.44) | HRH4 | |
| SCHEMBL18617538 | 0.74 | NOS3 (0.34) | — | |
| SCHEMBL22423835 | 0.74 | MPO (0.31) | CDK2MCHR1 | |
| SCHEMBL18585833 | 0.71 | MPO (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| WO-2017040449-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | PNP 227/4885CDK2 3311/4885FEN1 1003/4885 |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | PNP 227/4885CDK2 3311/4885FEN1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.